Roche (ROG.S) is increasingly confident it will continue to lift sales and profit even as cut-rate copies of the Swiss drugmaker’s older cancer medicines start to grab business next year, its chief executive said on Wednesday. Big wins for three new drugs in recent months have helped to offset what ... Read More »